Rein Therapeutics Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Rein Therapeutics Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Tangible Assets Ratio: Of every $100 the company owns, $18 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 97% of Healthcare companies in United States.
- Shareholder Slice Ratio: Share count rose 507% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
18%Of every $100 the company owns, $18 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 97% of Healthcare companies in United States.
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Rein Therapeutics Inc. made a loss over the last year. Rein Therapeutics Inc. owes $0.85 for every $1 it owns. Rein Therapeutics Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossRein Therapeutics Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
4.92The share price is 4.92 times Rein Therapeutics Inc.'s book value per share, higher than 72% of Healthcare companies in United States.
Market cap
$50 MThe total market value of all of Rein Therapeutics Inc.'s shares at today's price (share price × number of shares), smaller than 73% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$10 MWhat Rein Therapeutics Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.12Net worth divided by the number of shares. The share price of $0.58 is 4.9 times this, which is the P/B above.
Return on equity (ROE)
-96.4%Rein Therapeutics Inc. lost 96.4% of its shareholders' money over the last year, lower than 70% of Healthcare companies in United States.
Owes vs Owns
0.85×Rein Therapeutics Inc. owes $0.85 for every $1 it owns (high), higher than 80% of Healthcare companies in United States.
Dividend yield
NoneRein Therapeutics Inc. does not currently pay a dividend.
Profit growth
LossRein Therapeutics Inc. made a loss in each of the last two years.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Rein Therapeutics Inc.: $50 M ÷ $10 M (30 Jun 2026) = 4.9.
What is Rein Therapeutics Inc.'s return on equity?
Rein Therapeutics Inc. lost 96.4% of its shareholders' money over the last year, lower than 70% of Healthcare companies in United States.
How much does Rein Therapeutics Inc. owe compared with what it owns?
Rein Therapeutics Inc. owes $0.85 for every $1 it owns (high), higher than 80% of Healthcare companies in United States.
Does Rein Therapeutics Inc. pay a dividend?
No. Rein Therapeutics Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.